Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates

Antibody drug conjugates (ADCs) make up an important new modality that shows great results in treating certain types of cancer. Manufacturing this drug class is complex because it requires several Good Manufacturing Practices (GMP) intermediates as inputs to the conjugation reaction to produce the drug substance.

Our expert Chemistry, Manufacturing, and Controls (CMC) team conducted a detailed technical review to address the manufacturing challenges of ADCs. Read “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates” in the latest issue of BioProcess International (September 2023).

Scientific Articles
Published on:
September 20, 2023

Our experts behind the article “Manufacturing Challenges of Therapeutic Antibody-Drug Conjugates”:

  • Peter Alexander
  • Kelly Weitzel
  • Angela Linderholm
  • William E. Haskins
  • Sanjeevani Ghone
  • Steven M. Chamow

Contact us to discover how our team’s comprehensive knowledge in biologics and ADCs can make a significant difference in your development journey.

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.